Actos (pioglitazone), a new "glitazone" for type 2 diabetes.

Lilly is now marketing Actos (pioglitazone), a new "glitazone" for type 2 diabetes.

It's the second one to hit the market...after Avandia (rosiglitazone). Rezulin (troglitazone) was never marketed in Canada...and was pulled off the U.S. market due to liver toxicity.

Actos and Avandia lower blood glucose by improving insulin sensitivity.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote